 
MAINE STATE LEGISLATURE  
 
 
 
The following document is provided by the 
LAW AND LEGISLATIVE DIGITAL LIBRARY  
at the Maine State Law and Legislative Reference Library 
http://legislature.m aine.gov/lawlib 
 
 
 
 
 
 
 
 
 
 
Reproduced from electronic originals 
(may include minor formatting diffe rences from printed original) 
 
 
Printed on recycled paper131st MAINE LEGISLATURE
FIRST REGULAR SESSION-2023
Legislative Document No. 1395
S.P. 562 In Senate, March 28, 2023
An Act to Increase Transparency Regarding Certain Drug Pricing 
Programs
Reference to the Committee on Health Coverage, Insurance and Financial Services 
suggested and ordered printed.
DAREK M. GRANT
Secretary of the Senate
Presented by Senator TIPPING of Penobscot.
Cosponsored by Senator: BAILEY of York, Representatives: MATHIESON of Kittery, 
MORRIS of Turner, SKOLD of Portland.

Page 1 - 131LR1620(01)1Be it enacted by the People of the State of Maine as follows:
2Sec. 1.  22 MRSA ยง1728 is enacted to read:
3ยง1728.  Prescription drug transparency report
4 Beginning January 1, 2024, each hospital participating in the federal drug program 
5 under section 340b of the federal Public Health Service Act, 42 United States Code, Section 
6 256b shall provide an annual report to the Maine Health Data Organization. The Maine 
7 Health Data Organization shall post the report on a publicly accessible website. For the 
8 purposes of this section, "hospital" has the same meaning as in section 1843, subsection 4. 
9 Each hospital shall report in a standardized format specified by the Maine Health Data 
10 Organization and include the following in the report:
111.  Hospital data.  Hospital data separated by the hospital and each off-site clinic 
12 facility associated with the hospital including, but not limited to:
13 A.  Total annual revenue from drugs purchased under the 340b program less the 
14 aggregate annual acquisition costs for these drugs;
15 B.  Dispensing fees paid to contract pharmacies that the hospital contracts with to 
16 provide services associated with participation in the 340b program;
17 C.  Patient mix by payment source including, but not limited to, Medicare, the 
18 MaineCare program, private insurance and uninsured;
19 D.  Costs incurred for charity care; and
20 E.  Percentage of total revenue less discounts from infusion or injection of 
21 physician-administered drugs purchased through the 340b program, including any 
22 associated items or services provided as part of administering these drugs;
232.  Drug data.  Drug data for each hospital and the off-site clinic facility associated 
24 with the hospital from each dispensing site including:
25 A.  Name of the drug;
26 B.  National drug code;
27 C.  Acquisition cost;
28 D.  Type of account through which the drug was purchased and the associated 340b 
29 identification number, such as wholesaler, direct from the manufacturer or 
30 consignment;
31 E.  Quantity;
32 F.  Payer source including, but not limited to, Medicare and the MaineCare program, 
33 and primary, secondary or tertiary source;
34 G.  Date of prescription;
35 H.  Location where the 340b drug was administered or dispensed;
36 I.  Date the drug was administered or dispensed; and
37 J.  Compensation received from the sale of the 340b drug, including ingredient cost, 
38 dispensing fee and other compensation; and
Page 2 - 131LR1620(01)13.  Contracting and vendor data.  Contracting and vendor data separated by the 
2 hospital and each off-site clinic facility associated with the hospital including, but not 
3 limited to:
4 A.  The names of all 3rd-party vendors, including split billing vendors and contract 
5 pharmacies that the hospital contracts with to provide services associated with 
6 participation in the 340b program;
7 B.  List the self-negotiated contracts for individual entities and integrated delivery 
8 networks, including pharmacy benefits manager costs, insurance carriers and employer 
9 self-funded plans;
10 C.  Split billing vendor information, if used by the hospital, and total amounts paid for 
11 split billing services; and
12 D.  Grantee contract information and compensation paid.
134.  Reporting.  The Maine Health Data Organization shall produce and post on its 
14 publicly accessible website a report that includes a summary of the aggregate information 
15 received from hospitals and off-site clinic facilities associated with the hospital required to 
16 report under subsections 1 and 2. The Maine Health Data Organization shall submit the 
17 report required by this subsection to the Office of Affordable Health Care, the Maine 
18 Prescription Drug Affordability Board and the joint standing committee of the Legislature 
19 having jurisdiction over health data reporting and prescription drug matters.
20SUMMARY
21 This bill requires each hospital to provide an annual report to the Maine Health Data 
22 Organization with hospital data, drug data and contracting and vendor data related to its 
23 participation in the federal 340b drug pricing program. The Maine Health Data 
24 Organization must post the report on a publicly accessible website.21
22
23
24
